MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
March 11, 2024
FOR IMMEDIATE RELEASE: March 11, 2024 [San Jose, California 03/11/24] – The Multidisciplinary Association for Psychedelic Studies (MAPS) has partnered with the City and County of Denver to provide comprehensive …
MAPS Announces Celestial Plans for Its 38th Anniversary
March 7, 2024
FOR IMMEDIATE RELEASE: March 07, 2024 [San Jose, California 03/07/24] – MAPS (Multidisciplinary Association for Psychedelic Studies) is excited to announce its collaboration with Texas Eclipse 2024 for …
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
February 13, 2024
FOR IMMEDIATE RELEASE: February 13, 2024 [San Jose, California 02/13/24] – The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference …
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
February 9, 2024
FOR IMMEDIATE RELEASE: February 9, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) congratulates Lykos Therapeutics, formerly MAPS Public Benefit Corporation, on its announcement …
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024
FOR IMMEDIATE RELEASE: January 16, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces itsFiscal Sponsorship Program, signaling a new era of support for grassroots organizations …
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
January 5, 2024
FOR IMMEDIATE RELEASE: January 5, 2024 A decade after it was founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS …
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023
FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign
December 4, 2023
FOR IMMEDIATE RELEASE: December 4, 2023 Yesterday’s highly anticipated football game between the San Francisco 49ers and the Philadelphia Eagles brought additional excitement to the field thanks to 49ers’ …
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
November 11, 2023
FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …
MAPS Statement on Trauma and Crisis Response in Palestine and Israel
October 19, 2023
Many in the MAPS community are grieving the loss and suffering experienced by family, friends, colleagues, and countless others impacted by the Israel-Hamas war. At MAPS, we have been in deep dialogue …
PS2023: The Virtual Trip Unveils Latest Video Release Featuring Michael Pollan, Melissa Etheridge, and More
October 9, 2023
PS2023: The Virtual Trip, produced by the Multidisciplinary Association for Psychedelic Studies (MAPS), has published an additional 40 session videos from Psychedelic Science 2023, showcasing a trove of …
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
September 13, 2023
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
